Briumvi® (Ublituximab-Xiiy) – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare covers Briumvi (ublituximab‑xiiy) for adults with relapsing forms of multiple sclerosis when dosed per FDA labeling and not given concomitantly with listed disease‑modifying, B‑cell‑targeted, or lymphocyte‑trafficking therapies; authorizations are limited to 12 months. Initial approval requires documented diagnosis and FDA‑consistent dosing, and continuation requires prior Briumvi use with documentation of a positive clinical response and ongoing absence of excluded concomitant therapies.

"Briumvi (ublituximab-xiiy) is proven for the treatment of relapsing forms of multiple sclerosis (MS)."

Sign up to see full coverage criteria, indications, and limitations.